Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 355-366 , June 2009

Churg–Strauss angiitis

  • Renato A. Sinico, MD

      Affiliations

    • Clinical Immunology Unit, Department of Medicine, Azienda Ospedaliera Ospedale San Carlo Borromeo, via Pio Secondo, 3 – 20153 - Milano, Italy
    • Corresponding Author InformationCorresponding author. Clinical Immunology Unit (Head) and Renal Unit, Department of Medicine, Azienda Ospedaliera Ospedale San Carlo Borromeo, via Pio Secondo, 3 – 20153 - Milano, Italy. Tel.: +390240222489; Fax: +390240222222.
    • ,
  • Paolo Bottero, MD

      Affiliations

    • Allergy and Clinical Immunology Outpatient Clinic, Department of Medicine, Ospedale “G. Fornaroli” di Magenta, Azienda Ospedaliera di Legnano, via al Donatore di Sangue, 50 – 20013 - Magenta, Milano, Italy

References 

  1. Churg J, Strauss L. Allergic granulomatosis angiitis and periarteritis nodosa. Am J Pathol. 1951;27:277–294
  2. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–192
  3. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43:414–419
  4. Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription event monitoring cohort studies. Pharmacoepidemiol Drug Saf. 1999;8:179–189
  5. Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalence of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51:92–99
  6. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63:65–81
  7. Guillevin L, Cohen P, Gayraud M, et al. Churg Strauss syndrome: clinical study and long term follow-up of 96 patients. Medicine. 1999;78:26–37
  8. Eustace JA, Nadasdy T, Choi M. The Churg Strauss syndrome. J Am Soc Nephrol. 1999;10:2048–2055
  9. Conron M, Beynon HL. Churg-Strauss syndrome. Thorax. 2000;55:870–877
  10. Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol. 2001;14:1284–1293
  11. Noth I, Strek ME, Leff AR. Churg Strauss syndrome. Lancet. 2003;361:587–594
  12. Abril A, Calamia KT, Cohen MD. The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum. 2003;33:106–114
  13. Keogh KA, Specks U. Churg Strauss syndrome. Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115:284–290
  14. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss Syndrome. Arthritis Rheum. 2005;52:2926–2936
  15. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143:632–638
  16. Specks U. Diffuse alveolar hemorrhage syndromes. Curr Opin Rheumatol. 2001;13:12–17
  17. Reid AJC, Harrison BDW, Watts RA, et al. Churg Strauss syndrome in a district hospital. QJM. 1998;91:219–229
  18. Della Rossa A, Baldini C, Tavoni A, et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology. 2002;41:1286–1294
  19. Solans R, Bosch JA, Perez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology. 2001;40:763–771
  20. Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 2006;47:770–779
  21. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337:1512–1523
  22. Savage CO, Harper L, Adu D. Primary systemic vasculitis. Lancet. 1997;349:553–558
  23. Kallenberg CG, Brouwer E, Weening JJ, et al. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 46:1–15.
  24. Saleh A, Stone JH. Classification and diagnostic criteria in systemic vasculitis. Best Pract Res Clin Rheumatol. 2005;19:209–221
  25. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094–1100
  26. Sørensen SF, Slot O, Tvede N, et al. A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis. 2000;59:479–482
  27. Lane SE, Watts Sa, Barker TH, et al. Evaluation of the Sørensen diagnostic criteria in the classification of systemic vasculitis. Rheumatology. 2002;41:1138–1141
  28. Alberts WM. Pulmonary manifestations of the Churg-Strauss syndrome and related idiopathic small vessel vasculitis syndromes. Curr Opin Pulm Med. 2007;13:445–450
  29. Katzenstein AL. Diagnostic features and differential diagnosis of Churg-Strauss syndrome in the lung. A review. Am J Clin Pathol. 2000;114:767–772
  30. Wechsler ME. Pulmonary eosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27:477–492
  31. Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss syndrome. Chest. 1995;108:320–323
  32. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyartetritis nodosa for epidemiology studies. Ann Rheum Dis. 2007;66:222–227
  33. Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56:87–96
  34. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR Recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2008 Apr 15;[Epub ahead of print]
  35. Roufosse FE, Goldam M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis. 2007;2:37
  36. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 1998;53:743–753
  37. Kallenberg CG. Churg-Strauss syndrome: just one disease entity?. Arthritis Rheum. 2005;52:2589–2593
  38. Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol. 2007;19:25–32
  39. Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol. 2008;20:55–60
  40. Seo P, Stone JH. Small-vessel and medium-vessel vasculitis. Arthritis Rheum. 2007;57:1552–1559
  41. Vaglio A, Martorana D, Maggiore U, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum. 2008;56:3159–3166
  42. Wieczorek S, Hellmich B, Gross WL, Epplen JT. Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio, et al. Arthritis Rheum. 2008;58:329–330
  43. Wieczorek S, Hellmich B, Arning L, et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum. 2008;58:1839–1848
  44. Guillevin L, Jarrousse B, Lok C, et al. Long term follow up after treatment of polyarteritis nodosa and Churg–Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol. 1991;18:567–574
  45. Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg–Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol. 1997;36:1290–1297
  46. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss Syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75:17–28
  47. Ribi C, Cohen P, Pagnoux C, et al., French Vasculitis Study Group  Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58:586–594
  48. Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57:686–693
  49. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;3(349):36–44
  50. Loo KL, Ramachandran R, Chow SK, et al. Mononeuritis in Churg-Strauss syndrome in Asians responding to intravenous cyclophosphamide. Rheumatology (Oxford). 2004;43:251–252
  51. Hoi AY, Morand EF. Churg-Strauss syndrome: the use of cyclophosphamide in mononeuritis. Rheumatology (Oxford). 2003;42:390–391
  52. Jayne DR, Gaskin G, Rasmussen N. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–2188
  53. Danieli MG, Cappelli M, Malcangi G, et al. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis. 2004;63:1649–1654
  54. von Gunten S, Vogel M, Schaub A, et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol. 2007;119:1005–1011
  55. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med. 1998;129:370–374
  56. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology. 2002;206:496–501
  57. Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford). 2008;47:1104–1105
  58. Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med. 2006;355:1281–1282
  59. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60:302–308
  60. Bargagli E, Madioni C, Olivieri C, et al. Churg-Strauss vasculitis in a patient treated with omalizumab. J Asthma. 2008;45:115–116
  61. Ruppert AM, Averous G, Stanciu D, et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol. 2008;121:253–254
  62. Puéchal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med. 2008;19:364–366
  63. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol. 2007;144:155–158
  64. GINA . Global strategy for asthma management and prevention: update. Available from: htpp//www.ginasthma.org2007;
  65. McDanel DL, Muller BA. The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction?. Ther Clin Risk Manag. 2005;1:125–140
  66. Hauser T, Mahr A, Metzler C, et al. The leukotriene-receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 2008;63:677–682

PII: S1521-6942(09)00025-4

doi: 10.1016/j.berh.2009.02.004

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 355-366 , June 2009

Article Tools